Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina

Autores
Rodeles Antonelli, Luz María; Peverengo, Luz María; Benítez, Romina; Benzaquen, Nadia; Serravalle, Priscila; Long, Ana Karina; Ferreira, Virginia; Benitez, Agostina Daiana; Zunino, Luisina; Lizarraga, Camila; Vicco, Miguel Hernán
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Objective. To evaluate the seroprevalence of COVID-19 infection in pauci-symptomatic and asymptomatic people, the associated epidemiological factors, and IgG antibody kinetic over a 5-month period to get a better knowledge of the disease transmissibility and the rate of susceptible persons that might be infected. Methods. Seroprevalence was evaluated by a cross-sectional study based on the general population of Santa Fe, Argentina (non-probabilistic sample) carried out between July and November 2020. A subgroup of 20 seropositive individuals was followed-up to analyze IgG persistence. For the IgG anti-SARS-CoV-2 antibodies detection, the COVID-AR IgG® ELISA kit was used. Results. 3 000 individuals were included conforming asymptomatic and pauci-symptomatic groups (n=1 500 each). From the total sample, only 8.83% (n=265) presented reactivity for IgG anti-SARS-CoV-2. A significant association was observed between positive anti-SARS-CoV-2 IgG and a history of contact with a confirmed case; the transmission rate within households was approximately 30%. In the pauci-symptomatic group, among the seropositive ones, anosmia and fever presented an OR of 16.8 (95% CI 9.5-29.8) and 2.7 (95% CI 1.6-4.6), respectively (p <0.001). In asymptomatic patients, IgG levels were lower compared to pauci-symptomatic patients, tending to decline after 4 months since the symptoms onset. Conclusion. We observed a low seroprevalence, suggestive of a large population susceptible to the infection. Anosmia and fever were independent significant predictors for seropositivity. Asymptomatic patients showed lower levels of antibodies during the 5-month follow-up. IgG antibodies tended to decrease over the end of this period regardless of symptoms.
Fil: Rodeles Antonelli, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Peverengo, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Benítez, Romina. Centro de Especialidades Médicas; Argentina
Fil: Benzaquen, Nadia. Servicio de Cardiología Sanatorio de Diagnóstico y Tratamiento; Argentina
Fil: Serravalle, Priscila. Centro de Especialidades Médicas; Argentina
Fil: Long, Ana Karina. Centro de Especialidades Médicas; Argentina
Fil: Ferreira, Virginia. Centro de Especialidades Médicas; Argentina
Fil: Benitez, Agostina Daiana. Centro de Especialidades Médicas; Argentina
Fil: Zunino, Luisina. Centro de Especialidades Médicas; Argentina
Fil: Lizarraga, Camila. Centro de Especialidades Médicas; Argentina
Fil: Vicco, Miguel Hernán. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Materia
ANOSMIA
ARGENTINA
ASYMPTOMATIC DISEASES
EPIDEMIOLOGY
SARS-COV-2
SEROPREVALENCE
COVID-19
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/152097
Acceder
id CONICETDig_b32da052895faff31c444ec732d851cb
oai_identifier_str oai:ri.conicet.gov.ar:11336/152097
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in ArgentinaRodeles Antonelli, Luz MaríaPeverengo, Luz MaríaBenítez, RominaBenzaquen, NadiaSerravalle, PriscilaLong, Ana KarinaFerreira, VirginiaBenitez, Agostina DaianaZunino, LuisinaLizarraga, CamilaVicco, Miguel HernánANOSMIAARGENTINAASYMPTOMATIC DISEASESEPIDEMIOLOGYSARS-COV-2SEROPREVALENCECOVID-19https://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Objective. To evaluate the seroprevalence of COVID-19 infection in pauci-symptomatic and asymptomatic people, the associated epidemiological factors, and IgG antibody kinetic over a 5-month period to get a better knowledge of the disease transmissibility and the rate of susceptible persons that might be infected. Methods. Seroprevalence was evaluated by a cross-sectional study based on the general population of Santa Fe, Argentina (non-probabilistic sample) carried out between July and November 2020. A subgroup of 20 seropositive individuals was followed-up to analyze IgG persistence. For the IgG anti-SARS-CoV-2 antibodies detection, the COVID-AR IgG® ELISA kit was used. Results. 3 000 individuals were included conforming asymptomatic and pauci-symptomatic groups (n=1 500 each). From the total sample, only 8.83% (n=265) presented reactivity for IgG anti-SARS-CoV-2. A significant association was observed between positive anti-SARS-CoV-2 IgG and a history of contact with a confirmed case; the transmission rate within households was approximately 30%. In the pauci-symptomatic group, among the seropositive ones, anosmia and fever presented an OR of 16.8 (95% CI 9.5-29.8) and 2.7 (95% CI 1.6-4.6), respectively (p <0.001). In asymptomatic patients, IgG levels were lower compared to pauci-symptomatic patients, tending to decline after 4 months since the symptoms onset. Conclusion. We observed a low seroprevalence, suggestive of a large population susceptible to the infection. Anosmia and fever were independent significant predictors for seropositivity. Asymptomatic patients showed lower levels of antibodies during the 5-month follow-up. IgG antibodies tended to decrease over the end of this period regardless of symptoms.Fil: Rodeles Antonelli, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; ArgentinaFil: Peverengo, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; ArgentinaFil: Benítez, Romina. Centro de Especialidades Médicas; ArgentinaFil: Benzaquen, Nadia. Servicio de Cardiología Sanatorio de Diagnóstico y Tratamiento; ArgentinaFil: Serravalle, Priscila. Centro de Especialidades Médicas; ArgentinaFil: Long, Ana Karina. Centro de Especialidades Médicas; ArgentinaFil: Ferreira, Virginia. Centro de Especialidades Médicas; ArgentinaFil: Benitez, Agostina Daiana. Centro de Especialidades Médicas; ArgentinaFil: Zunino, Luisina. Centro de Especialidades Médicas; ArgentinaFil: Lizarraga, Camila. Centro de Especialidades Médicas; ArgentinaFil: Vicco, Miguel Hernán. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; ArgentinaOrganización Panamericana de la Salud2021-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/152097Rodeles Antonelli, Luz María; Peverengo, Luz María; Benítez, Romina; Benzaquen, Nadia; Serravalle, Priscila; et al.; Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina; Organización Panamericana de la Salud; Revista Panamericana de Salud Pública; 45; 1; 6-2021; 1-81020-4989CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.26633/RPSP.2021.66info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:03:18Zoai:ri.conicet.gov.ar:11336/152097instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:03:18.413CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina
title Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina
spellingShingle Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina
Rodeles Antonelli, Luz María
ANOSMIA
ARGENTINA
ASYMPTOMATIC DISEASES
EPIDEMIOLOGY
SARS-COV-2
SEROPREVALENCE
COVID-19
title_short Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina
title_full Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina
title_fullStr Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina
title_full_unstemmed Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina
title_sort Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina
dc.creator.none.fl_str_mv Rodeles Antonelli, Luz María
Peverengo, Luz María
Benítez, Romina
Benzaquen, Nadia
Serravalle, Priscila
Long, Ana Karina
Ferreira, Virginia
Benitez, Agostina Daiana
Zunino, Luisina
Lizarraga, Camila
Vicco, Miguel Hernán
author Rodeles Antonelli, Luz María
author_facet Rodeles Antonelli, Luz María
Peverengo, Luz María
Benítez, Romina
Benzaquen, Nadia
Serravalle, Priscila
Long, Ana Karina
Ferreira, Virginia
Benitez, Agostina Daiana
Zunino, Luisina
Lizarraga, Camila
Vicco, Miguel Hernán
author_role author
author2 Peverengo, Luz María
Benítez, Romina
Benzaquen, Nadia
Serravalle, Priscila
Long, Ana Karina
Ferreira, Virginia
Benitez, Agostina Daiana
Zunino, Luisina
Lizarraga, Camila
Vicco, Miguel Hernán
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ANOSMIA
ARGENTINA
ASYMPTOMATIC DISEASES
EPIDEMIOLOGY
SARS-COV-2
SEROPREVALENCE
COVID-19
topic ANOSMIA
ARGENTINA
ASYMPTOMATIC DISEASES
EPIDEMIOLOGY
SARS-COV-2
SEROPREVALENCE
COVID-19
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Objective. To evaluate the seroprevalence of COVID-19 infection in pauci-symptomatic and asymptomatic people, the associated epidemiological factors, and IgG antibody kinetic over a 5-month period to get a better knowledge of the disease transmissibility and the rate of susceptible persons that might be infected. Methods. Seroprevalence was evaluated by a cross-sectional study based on the general population of Santa Fe, Argentina (non-probabilistic sample) carried out between July and November 2020. A subgroup of 20 seropositive individuals was followed-up to analyze IgG persistence. For the IgG anti-SARS-CoV-2 antibodies detection, the COVID-AR IgG® ELISA kit was used. Results. 3 000 individuals were included conforming asymptomatic and pauci-symptomatic groups (n=1 500 each). From the total sample, only 8.83% (n=265) presented reactivity for IgG anti-SARS-CoV-2. A significant association was observed between positive anti-SARS-CoV-2 IgG and a history of contact with a confirmed case; the transmission rate within households was approximately 30%. In the pauci-symptomatic group, among the seropositive ones, anosmia and fever presented an OR of 16.8 (95% CI 9.5-29.8) and 2.7 (95% CI 1.6-4.6), respectively (p <0.001). In asymptomatic patients, IgG levels were lower compared to pauci-symptomatic patients, tending to decline after 4 months since the symptoms onset. Conclusion. We observed a low seroprevalence, suggestive of a large population susceptible to the infection. Anosmia and fever were independent significant predictors for seropositivity. Asymptomatic patients showed lower levels of antibodies during the 5-month follow-up. IgG antibodies tended to decrease over the end of this period regardless of symptoms.
Fil: Rodeles Antonelli, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Peverengo, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Benítez, Romina. Centro de Especialidades Médicas; Argentina
Fil: Benzaquen, Nadia. Servicio de Cardiología Sanatorio de Diagnóstico y Tratamiento; Argentina
Fil: Serravalle, Priscila. Centro de Especialidades Médicas; Argentina
Fil: Long, Ana Karina. Centro de Especialidades Médicas; Argentina
Fil: Ferreira, Virginia. Centro de Especialidades Médicas; Argentina
Fil: Benitez, Agostina Daiana. Centro de Especialidades Médicas; Argentina
Fil: Zunino, Luisina. Centro de Especialidades Médicas; Argentina
Fil: Lizarraga, Camila. Centro de Especialidades Médicas; Argentina
Fil: Vicco, Miguel Hernán. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
description Objective. To evaluate the seroprevalence of COVID-19 infection in pauci-symptomatic and asymptomatic people, the associated epidemiological factors, and IgG antibody kinetic over a 5-month period to get a better knowledge of the disease transmissibility and the rate of susceptible persons that might be infected. Methods. Seroprevalence was evaluated by a cross-sectional study based on the general population of Santa Fe, Argentina (non-probabilistic sample) carried out between July and November 2020. A subgroup of 20 seropositive individuals was followed-up to analyze IgG persistence. For the IgG anti-SARS-CoV-2 antibodies detection, the COVID-AR IgG® ELISA kit was used. Results. 3 000 individuals were included conforming asymptomatic and pauci-symptomatic groups (n=1 500 each). From the total sample, only 8.83% (n=265) presented reactivity for IgG anti-SARS-CoV-2. A significant association was observed between positive anti-SARS-CoV-2 IgG and a history of contact with a confirmed case; the transmission rate within households was approximately 30%. In the pauci-symptomatic group, among the seropositive ones, anosmia and fever presented an OR of 16.8 (95% CI 9.5-29.8) and 2.7 (95% CI 1.6-4.6), respectively (p <0.001). In asymptomatic patients, IgG levels were lower compared to pauci-symptomatic patients, tending to decline after 4 months since the symptoms onset. Conclusion. We observed a low seroprevalence, suggestive of a large population susceptible to the infection. Anosmia and fever were independent significant predictors for seropositivity. Asymptomatic patients showed lower levels of antibodies during the 5-month follow-up. IgG antibodies tended to decrease over the end of this period regardless of symptoms.
publishDate 2021
dc.date.none.fl_str_mv 2021-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/152097
Rodeles Antonelli, Luz María; Peverengo, Luz María; Benítez, Romina; Benzaquen, Nadia; Serravalle, Priscila; et al.; Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina; Organización Panamericana de la Salud; Revista Panamericana de Salud Pública; 45; 1; 6-2021; 1-8
1020-4989
CONICET Digital
CONICET
url http://hdl.handle.net/11336/152097
identifier_str_mv Rodeles Antonelli, Luz María; Peverengo, Luz María; Benítez, Romina; Benzaquen, Nadia; Serravalle, Priscila; et al.; Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina; Organización Panamericana de la Salud; Revista Panamericana de Salud Pública; 45; 1; 6-2021; 1-8
1020-4989
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.26633/RPSP.2021.66
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Organización Panamericana de la Salud
publisher.none.fl_str_mv Organización Panamericana de la Salud
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781262884241408
score 12.982451

Publicaciones similares